# BioPharma / Life Sciences (Institutional PDF)

- Date: 2026-02-08
- âœ… 3 PDF(s)
- ğŸ“„ Full-text: 3

---

## 1. Presentation - Evaluate `[ğŸ“„]`

ğŸ”— [evaluate.com](https://www.evaluate.com/wp-content/uploads/2024/02/World-Preview-Webinar_FINAL_0.pdf)

PHARMAâ€™S AGE OF
UNCERTAINTY
WORLD PREVIEW 2023 TO 2028


1 Evaluate 2023   I   Copyright Â© 2023 Evaluate Ltd. All rights reserved.   Source: Evaluate PharmaÂ© (Jun 2023)
TODAYâ€™S PRESENTERS
World preview 2022 to 2023




                                                                                                                  PAUL VERDIN
                                                                                                                  VP, Head of Consulting

---

## 2. TRANSFORM - Evaluate `[ğŸ“„]`

ğŸ”— [evaluate.com](https://www.evaluate.com/wp-content/uploads/2023/11/Evaluate-Omnium-Brochure.pdf)

TRANSFORM
asset potential assessment
with a richer understanding
of risk and return.




In todayâ€™s complex biopharma landscape, you need
an accurate and complete view of the market, so
you can thoroughly assess the development risk and
commercial potential of assets in development.
CLOSE KEY INSIGHT GAPS
The biopharma industry continues to invest far more in clinical failure
than success.

---

## 3. Review - accessdata.fda.gov `[ğŸ“„]`

ğŸ”— [fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/210496Orig1s017MultidisciplineR.pdf)

NDA/BLA Multi-disciplinary Review and Evaluation NDA 210496
               BRAFTOVIÂ® (encorafenib)

               NDA/BLA Multi-disciplinary Review and Evaluation

               Disclaimer: FDA review was conducted in conjunction with other regulatory authorities under
               Project Orbis. FDA collaborated with Health Canada (HC).

---

## Rejected candidates (37 total)

- âŒ `domain not in allowed list (www.wcgclinical.com)` â€” [www.wcgclinical.com](https://www.wcgclinical.com/wp-content/uploads/2025/01/Trends-and-Insights-for-2025.pdf) â€” _2025 Clinical Trial Trends & Insights_
- âŒ `domain not in allowed list (makingpharmaindustry.it)` â€” [makingpharmaindustry.it](https://makingpharmaindustry.it/wp-content/uploads/2025/03/iqvia-institute-rd-trends-2025-forweb.pdf) â€” _Global Trends in R&D 2025 - makingpharmaindustry.i_
- âŒ `blocked: HTTP 403` â€” [web-assets.bcg.com](https://web-assets.bcg.com/9b/75/1c0db8bf4ee5b159b1d732ab6f1e/focusing-on-innovation-amid-complexity-jan-2025.pdf) â€” _Biopharma Trends 2025 - web-assets.bcg.com_
- âŒ `domain not in allowed list (pharmaphorum.com)` â€” [pharmaphorum.com](https://pharmaphorum.com/sites/default/files/2025-01/Life-Sciences-Industry-Report-2025-pt4.pdf) â€” _LIFE SCIENCES INDUSTRY REPORT 2025 - pharmaphorum._
- âŒ `domain not in allowed list (resources.indegene.com)` â€” [resources.indegene.com](https://resources.indegene.com/indegene/articles/global-life-sciences-industry-trends-2025.pdf) â€” _Global Life Sciences Industry Trends 2025_
- âŒ `domain not in allowed list (www.jpmorgan.com)` â€” [www.jpmorgan.com](https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q4-2025.pdf) â€” _Q4 2025 Biopharma Licensing and Venture Report - J_
- âŒ `domain not in allowed list (www.gibsondunn.com)` â€” [www.gibsondunn.com](https://www.gibsondunn.com/wp-content/uploads/2025/01/Life-Sciences-2025-Outlook-Brochure.pdf) â€” _LIFE SCIENCES_
- âŒ `domain not in allowed list (www.gayaherald.com)` â€” [www.gayaherald.com](https://www.gayaherald.com/story/350997/pi3k-inhibitors-market-clinical-trials-outlook-evaluating-25-drug-candidates-across-20-active-companies-by-delveinsight.html) â€” _PI3K Inhibitors Market & Clinical Trials Outlook :_

_...+29 more_

